An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Iveric Bio (NASDAQ: ISEE) announced on May 2, 2022, that it granted equity-based awards to six newly-hired, non-executive employees under its 2019 Inducement Stock Incentive Plan. These grants, approved by the compensation and talent strategy committee, included 156,000 non-statutory stock options and 13,500 restricted stock units, aimed at attracting talent. The stock options have an exercise price of $14.29 and a ten-year term, with a vesting schedule of four years. Iveric Bio focuses on developing treatments for retinal diseases.
Positive
Granted 156,000 stock options and 13,500 restricted stock units to enhance talent acquisition.
Stock options priced at $14.29, aligning with market value, potentially motivating employee performance.
Negative
None.
PARSIPPANY, N.J.--(BUSINESS WIRE)--
IVERIC Bio, Inc. (NASDAQ: ISEE) today reported that on May 2, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to six newly-hired, non-executive employees. These inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.
The inducement grants consisted of non-statutory stock options to purchase an aggregate of 156,000 shares of the Company’s common stock and an aggregate of 13,500 restricted stock units for shares of the Company’s common stock.
The stock options each have an exercise price of $14.29 per share, equal to the closing price of Iveric Bio’s common stock on May 2, 2022. The stock options each have a ten-year term and vest over four years, with 25% of the shares underlying each option vesting on May 2, 2023 and an additional 2.0833% of the shares underlying each option vesting at the end of each successive month thereafter. A tranche of 5,500 restricted stock units vests with respect to 100% of the shares underlying the units on April 1, 2023. A tranche of 1,000 restricted stock units vests with respect to 100% of the shares underlying the units on October 1, 2022. A tranche of 1,000 restricted stock units vest with respect to 50% of the shares underlying the applicable units on September 1, 2022 and the remaining 50% of the shares underlying the applicable units on April 1, 2023. A tranche of 3,000 restricted stock units vests with respect to 50% of the shares underlying the applicable units on July 1, 2022 and the remaining 50% of the shares underlying the applicable units on January 1, 2023. A tranche of 3,000 restricted stock units vests with respect to 25% of the shares underlying the units on each of May 2, 2023, May 2, 2024, May 2, 2025 and May 2, 2026. The vesting of the grants is subject to the applicable employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.
Iveric Bio Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.
